Coherus Oncology (CHRS) Cash from Financing Activities (2014 - 2026)
Coherus Oncology's Cash from Financing Activities was $144,000 in Q2 2026, compared with -$281.52 million a year earlier and down 99.7% from the prior quarter.
Powered by 
Analysis
Coherus Oncology (CHRS) Cash from Financing Activities (2014 - 2026) Analysis & Trends
On a trailing twelve-month basis, Coherus Oncology's Cash from Financing Activities was $61.82 million through Jun 30, 2026; for FY2025, it came in at -$273.71 million.
- In earlier years, Cash from Financing Activities was -$186.97 million in FY2024, $69.6 million in FY2023 (+28.1%), $54.33 million in FY2022 (+4.7%) and $51.88 million in FY2021 (-76.8%).
- Quarterly Cash from Financing Activities has moved between -$281.52 million (Q2 2025) and $54.33 million (Q2 2023) over five years.
- The best year-over-year quarter for Cash from Financing Activities over five years was Q4 2022 (growth of 343.4%); the worst was Q2 2022 (a decline of 98.5%).
- Per Business Quant data, CHRS's Cash from Financing Activities in the three quarters before Q2 2026 was $53.59 million (Q1 2026), $8.08 million (Q4 2025) and $2,000 (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,122.91 Bn | 1,091.50 Bn | 19.71 Bn | 8.43 Bn |
| 2 | Johnson & Johnson | 615.09 Bn | 533.62 Bn | 17.26 Bn | -8.78 Bn |
| 3 | AbbVie | 504.75 Bn | 477.86 Bn | 12.70 Bn | -5.05 Bn |
| 4 | Merck | 360.18 Bn | 314.55 Bn | 12.21 Bn | 1.76 Bn |
| 5 | Novartis Ag | 292.05 Bn | 256.04 Bn | 11.24 Bn | -2.02 Bn |
| 6 | Astrazeneca | 256.09 Bn | 229.78 Bn | 12.86 Bn | -3.89 Bn |
| 7 | Amgen | 233.63 Bn | 189.02 Bn | 7.24 Bn | -1.48 Bn |
| 8 | Gilead Sciences | 194.49 Bn | 168.69 Bn | 6.22 Bn | 2.34 Bn |
| 9 | Pfizer | 168.35 Bn | 114.99 Bn | 10.94 Bn | -3.66 Bn |
| 10 | Coherus Oncology | 155.59 Mn | -480.55 Mn | 10.07 Mn | 144,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 144,000.00 |
| Mar 31, 2026 | 53.59 Mn |
| Dec 31, 2025 | 8.08 Mn |
| Sep 30, 2025 | 2,000.00 |
| Jun 30, 2025 | -281.52 Mn |
| Mar 31, 2025 | -264,000.00 |
| Dec 31, 2024 | 231,000.00 |
| Sep 30, 2024 | -167,000.00 |
| Jun 30, 2024 | -187.93 Mn |
| Mar 31, 2024 | 887,000.00 |
| Dec 31, 2023 | 366,000.00 |
| Sep 30, 2023 | 11.11 Mn |
| Jun 30, 2023 | 54.33 Mn |
| Mar 31, 2023 | 3.80 Mn |
| Dec 31, 2022 | 6.59 Mn |
| Sep 30, 2022 | 48.87 Mn |
| Jun 30, 2022 | 721,000.00 |
| Mar 31, 2022 | -1.86 Mn |
| Dec 31, 2021 | 1.49 Mn |
| Sep 30, 2021 | 1.10 Mn |
API Access
Coherus Oncology Cash from Financing Activities API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=CHRS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-from-financing-activities", "ticker": "CHRS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=CHRS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();